Revance price target raised to $30 from $22 at Wells Fargo

Wells Fargo raised the firm’s price target on Revance to $30 from $22 and keeps an Equal Weight rating on the shares. Setup The firm notes that Cervical Dystonia sNDA implied high POS for approval plus smaller market, and valuation looks fair near-term.